BBP-398, CETUXIMAB, ADAGRASIB
CA126-0015
Phase 2 small_molecule active
Quick answer
BBP-398, CETUXIMAB, ADAGRASIB for Oncology, NSCLC and CRC is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Oncology, NSCLC and CRC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active